Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,236 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Disorder Clear all
Recruiting No phase listed Observational

Baker Gordon Syndrome Natural History Study

NCT06399952
View directory record Official record
Conditions
Rare Diseases, Autism or Autistic Traits, Development Delay, SYT-SSX Fusion Protein Expression, Sleep Disorder, Epilepsy, Generalized, Motor Delay
Interventions
Brain Magnetic Resonance Imaging (MRI), Whole Genome Sequencing, Induced Pluripotential Stem Cells
Diagnostic Test · Genetic · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
0 Years to 99 Years
Enrollment
50 participants
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

NCT00104416
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine (LAMICTAL) extended-release, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
64
States / cities
Anniston, Alabama • Birmingham, Alabama • Northport, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Apioc Presbyopic Contact Lens

NCT04437732
View directory record Official record
Conditions
Presbyopia, Refractive Errors
Interventions
Apioc-P and Apioc-PT Contact Lens Design
Device
Lead sponsor
Lentechs, LLC
Industry
Eligibility
40 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Athens, Ohio • Powell, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544750
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 2 Interventional Results available

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115
View directory record Official record
Conditions
Epilepsy
Interventions
A=Placebo, B=Inhaled Alprazolam 0.5 mg, C=Inhaled Alprazolam 1 m, D= Inhaled Alprazolam 2 mg, E=Placebo
Drug
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Boise, Idaho • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Completed No phase listed Observational

Human Epilepsy Project 2: Resistant Focal Seizures Study

NCT03531008
View directory record Official record
Conditions
Epilepsy, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Biomarkers
Interventions
Not listed
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
16 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 20, 2026, 6:46 AM EDT
Not yet recruiting Early Phase 1 Interventional

Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring

NCT07821697
View directory record Official record
Conditions
Epilepsy (Treatment Refractory)
Interventions
EEG Record only
Device
Lead sponsor
Adraxe Corp.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History of Treated Neurocysticercosis and Long-Term Outcomes

NCT00001205
View directory record Official record
Conditions
Cysticercosis, Neurocysticercosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1985
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

NCT01390220
View directory record Official record
Conditions
Epilepsy
Interventions
USL261, Placebo
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

NCT02408523
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide Tablet, Lasosamide Oral Solution, Placebo Tablet, Placebo Oral Solution
Drug · Other
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
4 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
27
States / cities
Alabaster, Alabama • Little Rock, Arkansas • Irvine, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786
View directory record Official record
Conditions
Seizures, Primary Motor Cortex, Brain Metastases From Non-small Cell Lung Cancer (NSCLC), Brain Metastases, Adult, Brain Metastases From Extra-cranial Solid Tumors
Interventions
Levetiracetam (Keppra)
Drug
Lead sponsor
Ayal A. Aizer, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Withdrawn Phase 2 Interventional

ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

NCT05481905
View directory record Official record
Conditions
Focal Epilepsy
Interventions
ENX-101
Drug
Lead sponsor
Engrail Therapeutics INC
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Phoenix, Arizona • Tucson, Arizona • Downey, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 20, 2026, 6:46 AM EDT
Completed No phase listed Observational

Magnetoencephalography in Absence Seizures

NCT00884351
View directory record Official record
Conditions
Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
7 Years to 35 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Capturing Autobiographical Memory Formation in Real World Spaces Using Multimodal Recordings

NCT06883981
View directory record Official record
Conditions
Epilepsy, Autobiographical Memory
Interventions
Free and Cued Recall Memory. Temporal Sequence and Spatial Memory
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 1 Interventional

Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy

NCT06387186
View directory record Official record
Conditions
Refractory Epilepsy, Drug Resistant Epilepsy
Interventions
Leucine-Enriched Essential Amino Acid powder
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
2 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting Not applicable Interventional

Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation

NCT02846272
View directory record Official record
Conditions
Intractable Epilepsy
Interventions
Observation
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
0 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 20, 2026, 6:46 AM EDT
Enrolling by invitation No phase listed Observational

SLC13A5 Deficiency Natural History Study - Remote Only

NCT04681781
View directory record Official record
Conditions
Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (non-ROGDI), 17p13.1 Deletions Confined to SLC13A5 Gene, Citrate Transporter Disorder
Interventions
Not listed
Lead sponsor
TESS Research Foundation
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 3 Interventional Results available

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

NCT01484977
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Huntsville, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 20, 2026, 6:46 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

GABA/Glutamate Balance in Temporal Lobe Epilepsy With and Without Major Depression

NCT00931619
View directory record Official record
Conditions
Epilepsy, Epilepsy, Temporal Lobe, Depression, Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 20, 2026, 6:46 AM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050934
View directory record Official record
Conditions
Epilepsy, Epilepsies, Partial
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 3 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
26
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting Not applicable Interventional

Telephone-Based Support Programs for People With Epilepsy

NCT05082181
View directory record Official record
Conditions
Epilepsy
Interventions
UPLIFT (Using Practice and Learning to Increase Favorable Thoughts), BOOST (Bringing Out Our Strength Together)
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 6:46 AM EDT
Recruiting No phase listed Observational

Epilepsy Learning Healthcare System (ELHS)

NCT06265103
View directory record Official record
Conditions
Epilepsy, Seizure Disorder, Neurologic Disorder, Rare Diseases
Interventions
Clinical care and quality improvement
Other
Lead sponsor
Epilepsy Foundation of America
Other
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2099
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 20, 2026, 6:46 AM EDT